CD44 and cancer: By using the introduction of a novel CDHA gatekeeper and the specific interaction with the Fc molecule, the MOS-Fc-CDHA nanocomposites protected the drug leakage, controlled the drug release by the enzyme (HAase), and provided the selective internalization to the CD44-overexpressing cancer cells.